Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of Zamicastat in Healthy Men
NCT04991181Phase 1Completed
- Sponsor
- BIAL
- Start
- Mar 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zamicastat in pulmonary arterial hypertension (PAH), sponsored by BIAL. Primary endpoints: Maximum Observed Plasma Concentration up to 20 days, Time to Maximum Plasma Concentration up to 20 days and 9 more. Started Mar 2017; status: completed.
02
Drugs
zamicastat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04991181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04991181.